Historique
Article de Périodique
Pharmacotherapy for smoking cessation: present and future (2011)
Auteur(s) :
AUBIN, H. J. ;
KARILA, L. ;
REYNAUD, M.
Année
2011
Page(s) :
1343-1350
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
125
Domaine :
Tabac / Tobacco / e-cigarette
Thésaurus mots-clés
ARRET DU TABAC
;
TABAC
;
ABSTINENCE
;
SEVRAGE
;
PHARMACOTHERAPIE
;
SUBSTITUTS NICOTINIQUES
;
BUPROPION
;
VARENICLINE
;
METHODE
Résumé :
Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review indentifies a series of promising drugs that hopefully will be available to complete our current armory.
Affiliation :
Substance Abuse Treatment Center, Hopital Paul Brousse, Hopitaux Universitaires Paris-Sud, AP-HP, INSERM U669 University Paris-Sud, Villejuif, France